Effect of Anesthesia on Intraocular Pressure Measured With Continuous Wireless Telemetry in Nonhuman Primates

Jessica V. Jasien,1 Christopher A. Girkin,2 and J. Crawford Downs2

1Vision Science Graduate Program, School of Optometry, University of Alabama at Birmingham, Birmingham, Alabama, United States
2Department of Ophthalmology and Visual Sciences, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States

Correspondence: J. Crawford Downs, Department of Ophthalmology and Visual Sciences The University of Alabama at Birmingham School of Medicine, 1670 University Blvd., VH 390A Birmingham, AL 35294, USA; cdowns@uab.edu.
Submitted: June 25, 2019
Accepted: August 9, 2019
Citation: Jasien JV, Girkin CA, Downs CJ. Effect of anesthesia on intraocular pressure measured with continuous wireless telemetry in nonhuman primates. Invest Ophthalmol Vis Sci. 2019;60:3830–3834. https://doi.org/10.1167/iovs.19-27758

PURPOSE. To compare the effects of both injectable anesthesia (ketamine/dexmedetomidine versus ketamine/xylazine) and inhalant anesthesia (isoflurane) on IOP using continuous, bilateral IOP telemetry in nonhuman primates (NHP).

METHODS. Bilateral IOP was recorded continuously using a proven implantable telemetry system in five different sessions at least 2 weeks apart in four male rhesus macaques under two conditions: ketamine (3 mg/kg) with dexmedetomidine (50 μg/kg) or ketamine with xylazine (0.5 mg/kg) for induction, both followed by isoflurane for maintenance. IOP transducers were calibrated via anterior chamber manometry. Bilateral IOP was averaged over 2 minutes after injectable anesthetic induction and again after isoflurane inhalant had stabilized the anesthetic plane, then compared to baseline IOP measurements acquired immediately prior to anesthesia (both before and after initial human contact).

RESULTS. When compared to pre-contact baseline measurements, ketamine/dexmedetomidine injectable anesthesia lowers IOP by 1.5 mm Hg on average (P < 0.05), but IOP did not change with ketamine/xylazine anesthesia. IOP returned to baseline levels shortly after isoflurane gas anesthesia was initiated. However, injectable anesthesia lowered IOP by an average of 5.4 mm Hg when compared to that measured after initial human contact (P < 0.01).

CONCLUSIONS. Anesthetic effects on IOP are generally small when compared to precontact baseline but much larger when compared to IOP measures taken after human contact, indicating that IOP is temporarily elevated due to acute stress (similar to a “white coat effect”) and then decreased with anesthetic relaxation. Anesthetic induction with ketamine/xylazine and maintenance with isoflurane gas should be used when IOP is measured postanesthesia.

Keywords: intraocular pressure, Anesthesia, Telemetry

General anesthesia is common in both animal studies and human patient procedures, but the effects of injectable and inhalant anesthesia on IOP have not been fully characterized. IOP is the only known treatable risk factor for glaucoma; therefore, the effects of anesthesia on IOP are important to know, especially for glaucoma studies involving IOP measurement under anesthesia. IOP is one of the primary modifiable variables in many research studies, and IOP is often experimentally elevated in research animals to induce experimental glaucoma for the study of downstream effects. Hence, accurately quantifying IOP in the research setting is extremely important, as artifacts due to anesthesia or animal handling could confound reported results. In particular, nonhuman primates (NHPs) are considered an important animal model in glaucoma studies and IOP measurements are difficult to obtain in awake, behaving animals, requiring most researchers to assume that IOP measurements in anesthetized NHPs accurately reflect the true IOP.

The effects of anesthesia on IOP have been studied in both animal models and human patients using single time-point (snapshot) IOP measurements, but comparisons were not made to true naïve baseline IOP since only postcontact and/or postanesthesia IOP measurements were obtained. Studies have shown that contact with a clinician or human animal handler can acutely elevate IOP.1–7 Ketamine is an NMDA receptor antagonist anesthetic that is commonly used in animal studies and in ophthalmic procedures involving children and uncooperative patients. Dexmedetomidine and xylazine are commonly used in conjunction with ketamine as an injectable anesthetic, and both are known to lower IOP.8–13 Dexmedetomidine is a synthetic alpha2-adrenoreceptor agonist with sedative and analgesic properties, and xylazine is an analogue of clonidine and an alpha2 adrenergic receptor agonist. Isoflurane is a halogenated ether used as an inhalation anesthesia, commonly after induction with injectables such as ketamine along with either dexmedetomidine or xylazine.

Human studies have reported both increases and decreases in IOP following ketamine injection alone, along with a dependence on dosage.14–17 so there is some confusion in the literature as to the effects of ketamine on IOP. The most common animal models in which the effects of anesthesia on IOP have been studied are rodents, sheep, and NHPs; other
studies have also included rabbits, cows, pigs, dogs, and cats.\textsuperscript{18–22} Raposo et al. reported the effect of four different anesthetics on capuchin monkeys, which included ketamine-xylazine and ketamine-dexmedetomidine.\textsuperscript{23} In their study, IOP was measured at four different time points after anesthetic induction with a contact tonometer (Tono-Pen; Reichert, Depew, New York, USA); importantly, a baseline IOP was not obtained prior to injection. Similarly, Bunch et al. examined the effect of ketamine on IOP in cynomolgus monkeys hourly over a 6-hour period with measurements taken with a Goldmann tonometer, but again, preanesthesia baseline IOP was not measured. Compared to postanesthesia baseline IOP, results showed a 2 to 6 mm Hg reduction in IOP over consecutive days measured. Compared to postanesthesia baseline IOP, results showed a 2 to 6 mm Hg reduction in IOP over consecutive days measured. Although these studies did not investigate the effect of different anesthetic regimens, they highlighted the importance of considering the effects of anesthetics on IOP in animal models.

Continuous IOP telemetry allows us to obtain IOP readings in awake, unrestrained NHPs without human contact, thereby establishing a true baseline IOP and quantifying second-to-second IOP changes that may be missed by single-time-point measurements. In this study, we used continuous IOP telemetry to quantify true baseline IOP in awake, behaving NHPs prior to human contact, after human interaction but prior to anesthetic induction, after induction with common injectable anesthetics (ketamine with dexmedetomidine or ketamine with xylazine), and after anesthetic plane was achieved with inhalant anesthesia. We report the effect of the different types of anesthesia on IOP in NHPs, which is especially important for glaucoma researchers that employ the NHP model of glaucoma. IOP is generally measured in NHPs after anesthetic induction, potentially confounding analyses of the effects of IOP on research outcomes. Hence, the effect of injectable and inhalant anesthesia on IOP is important in clinical assessment of mean IOP and research studies that rely upon experimental perturbations in IOP measured with snapshot devices.

**METHODS**

** Animals **

All animals were treated in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research under a protocol approved and monitored by the UAB Institutional Animal Care and Use Committee. Four adult male rhesus macaques (4–6 years) with no ocular abnormalities were used for anesthesia data collection as a part of a larger NIH-funded study aimed at determining the contributions of IOP fluctuations to glaucoma pathophysiology. All animals were kept on a 6 AM to 6 PM light-dark cycle and fed ad libitum through a continuous feed. Food and water intake were not measured for this study. NHP 9028 had the IOP telemetry system functioning only in the left eye (OS); therefore, data were only collected in the left eye for this animal. All animals were intubated postinjection and prior to isoflurane initiation. Standard intubation technique was used, with no topical anesthetic spray.
Ketamine/Xylazine

Table 2. Mean ± Standard Deviation of IOP, MAP, and HR

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Preinjection</th>
<th>Postinjection</th>
<th>Preisoflurane</th>
<th>Postisoflurane</th>
</tr>
</thead>
<tbody>
<tr>
<td>IOP-OD (mm Hg)</td>
<td>14.6 ± 1.7</td>
<td>18.8 ± 2.1*</td>
<td>13.1 ± 1.8†</td>
<td>13.9 ± 3.4</td>
<td>14.4 ± 0.5</td>
</tr>
<tr>
<td>IOP-OS (mm Hg)</td>
<td>14.1 ± 1.6</td>
<td>18.9 ± 1.8†</td>
<td>12.9 ± 1.6*</td>
<td>13.5 ± 2.4</td>
<td>14.4 ± 0.5</td>
</tr>
<tr>
<td>MAP (mm Hg)</td>
<td>108 ± 20</td>
<td>157 ± 26†</td>
<td>138 ± 25†</td>
<td>124 ± 26*</td>
<td>111 ± 24</td>
</tr>
<tr>
<td>HR (BPM)</td>
<td>128 ± 21</td>
<td>175 ± 36†</td>
<td>86 ± 13†</td>
<td>74 ± 14†</td>
<td>79 ± 14†</td>
</tr>
</tbody>
</table>

Ketamine/Dexmedetomidine

Measurements taken at baseline, preinjection, postinjection, preisoflurane timepoints for ketamine/dexmedetomidine or ketamine/xylazine, and post-isoflurane across all 4 NHPs and sessions.

*P < 0.05 indicate significant change relative to precontact baseline.
†P < 0.01.

P < 0.05 indicating a significant change. A comparison of the use of intramuscular injectable anesthesia, ketamine with xylazine or ketamine with dexmedetomidine was investigated for the change in IOP in the four NHPs.

**RESULTS**

Table 2 shows the mean response of IOP, MAP, and HR to both forms of injectable anesthesia followed by inhalant anesthesia compared to baseline values acquired before human contact (baseline), as well as the period just prior to injection when staff were in the room with the NHPs (preinjection). Results show that IOP increases by an average of 4.6 mm Hg just prior to anesthetic injections (preinjection) compared to precontact baseline in both conditions and all eyes (P < 0.05), and significantly decreases by 5.4 mm Hg immediately after the animals are immobilized by injectable anesthetics (P < 0.01). Compared to precontact baseline, however, IOP was significantly lower by only 1.5 mm Hg after ketamine/dexmedetomidine anesthetic induction (P < 0.05), with no significant IOP change occurring with either ketamine/xylazine injectable anesthesia or isoflurane inhalant anesthesia. There was no significant difference between the postinjection and preisoflurane IOP for either injectable anesthetic, indicating that IOP did not change significantly in the postinjection period once the animals were immobilized after induction. However, there was considerably more variability in the IOP measurements at the preisoflurane timepoint in the ketamine/dexmedetomidine sessions, so the preisoflurane IOP was not significantly different from baseline, whereas the postinjection IOPs were significantly lower than baseline. MAP and HR are significantly higher just prior to anesthetic injections and after induction with injectable anesthesia when compared to precontact baseline (P < 0.01), but MAP generally returns to near baseline levels after inhalant anesthesia is initiated; HR was significantly lower than baseline after inhalant anesthetic plane is reached (P < 0.01).

The Figure shows the responses of IOP, MAP, and HR relative to precontact baseline in each NHP by session; results show that the changes are animal and session specific, although they follow the general trends shown in Table 2. Interanimal and intereye analyses were not performed due to the limited sample size, although fellow eyes within animals followed a very similar pattern within individual sessions (Figure). In general, intersession and interanimal variability was higher than variability between fellow eyes within animals.

**DISCUSSION**

Results show that changes in IOP with injectable and inhalant anesthesia relative to precontact baseline are generally small, which bodes well for clinical and animal research activities that rely on postanesthesia IOP measurements. Both this study and a recent study from our group show that acute stress associated with human contact significantly elevates IOP, MAP, and HR in NHPs, demonstrating the importance of measuring IOP using telemetry that doesn’t require human contact. Anesthesia did lower IOP significantly when compared to IOP measured when the NHPs are in contact with staff (mean decrease of 5.4 mm Hg), but this is likely to be due to the relaxation of the animals from a stressful state and not the pharmacologic effects of the anesthesia itself, as postulated in prior NHP and human studies. Previous studies have shown that changes in IOP can be modulated through relaxation of the extraocular muscles, which could be the mechanism through which anesthesia acutely lowers IOP when the subject is stressed and IOP is acutely elevated as a result. Continuous IOP measurement via implanted transducers also has the advantage of avoiding ocular contact for IOP measurement that may affect IOP. In previous studies, IOP measurements were obtained with tonometers that rely on corneal appplanation. Tonometers were used to measure IOP only a few minutes apart in some studies, and repeated tonometry readings have been shown to reduce IOP.

The results of this study show that ketamine/dexmedetomidine injectable anesthesia lowers IOP by 1.5 mm Hg compared to baseline, but IOP returned to baseline levels shortly after isoflurane gas anesthesia was initiated. Although the reported effects are generally small and vary by animal and session, IOP changes with ketamine/dexmedetomidine anesthesia should be considered when IOP or its effects are important, especially when IOP is measured immediately after the animals are immobilized. Ketamine/xylazine did not significantly affect IOP in NHPs compared to preanesthesia baseline, and therefore should be considered as a preferred method of induction for NHP glaucoma research studies where IOP is measured immediately after induction. Also, isoflurane did not alter IOP irrespective of the injectable anesthesia used, so it remains a good option for studies in which IOP is measured after inhalant anesthesia has stabilized both the anesthetic plane and IOP. The MAP and HR data presented are consistent with previous reports, which shows an overall decrease in HR with the use of injectable and inhalant anesthesia. The MAP increased with the use of the injectable anesthesia and returned to near baseline levels with inhalant anesthesia.
The study is subject to the following limitations. First, we used ketamine with dexmedetomidine or xylazine, followed by isoflurane, instead of ketamine or inhalant anesthesia alone for induction as is most common in human patients. However, NHP studies commonly employ the anesthetics tested; therefore, the results are directly comparable to those studies. Second, the sample size was limited, although results were consistent and significant differences were found even with a relatively small effect size of 1.5 mm Hg; increasing the sample size would be unlikely to yield different results from those reported herein. That said, the results may not reflect the response of the full population of NHPs, and may not translate directly to human patients. Leveraging continuous IOP telemetry to obtain true precontact baseline IOP in an animal model that is similar to humans both anatomically and pharmacokinetically, provides unique insight into the true effects of anesthesia on IOP.

Overall, IOP changes due to injectable and inhalant anesthesia were generally small when compared to precontact baseline measurements. However, there was a significant anesthesia-related decrease in IOP of 5.4 mm Hg when compared to that measured after human contact was initiated, indicating that IOP was temporarily elevated due to acute stress (similar to a “white coat effect”) and then decreased with anesthetic relaxation. This is consistent with a prior report\(^1\) and should be considered in both experiments and clinical practice when consideration of IOP or its effects is important.

**Acknowledgments**

The authors thank Lisa Hethcox, LVT, for her help in both the care of the NHPs and data acquisition; and Chester Calvert and Ryan Whitley for their assistance in data procurement and processing. Supported by NIH Grants R01 EY024732 (JCD), R01 EY026035 (JCD) and P30 EY003039 (Samuels; UAB NEI Core Infrastructure grant); EyeSight Foundation of Alabama; Research to Prevent Blindness.

Disclosure: J.V. Jasien, None; C.A. Girkin, None; J.C. Downs, None

**References**


